世界のヒトマイクロバイオーム治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV12254)
◆英語タイトル:Global Human Microbiome Therapeutics Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV12254
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:95
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートはヒトマイクロバイオーム治療薬の世界市場について調査・分析した資料です。種類別(FMT、マイクロバイオーム薬)の市場規模、用途別(クロストリジウム・ディフィシル、クローン病、炎症性腸疾患、糖尿病、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別ヒトマイクロバイオーム治療薬の競争状況、市場シェア
・世界のヒトマイクロバイオーム治療薬市場:種類別市場規模 2015年-2020年(FMT、マイクロバイオーム薬)
・世界のヒトマイクロバイオーム治療薬市場:種類別市場規模予測 2021年-2026年(FMT、マイクロバイオーム薬)
・世界のヒトマイクロバイオーム治療薬市場:用途別市場規模 2015年-2020年(クロストリジウム・ディフィシル、クローン病、炎症性腸疾患、糖尿病、その他)
・世界のヒトマイクロバイオーム治療薬市場:用途別市場規模予測 2021年-2026年(クロストリジウム・ディフィシル、クローン病、炎症性腸疾患、糖尿病、その他)
・北米のヒトマイクロバイオーム治療薬市場分析:米国、カナダ
・ヨーロッパのヒトマイクロバイオーム治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのヒトマイクロバイオーム治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のヒトマイクロバイオーム治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのヒトマイクロバイオーム治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Enterome Bioscience、Rebiotix、Seres Therapeutics、Vedanta Biosciences、Bristol-Myers Squibb、Johnson & Johnson、Takeda Pharmaceutical
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Microbiome therapeutics are therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyse the establishment of healthy ones.
One of the major drivers for this market is side effects of the existing treatments. Various medicines available in the market have several side-effects including minor headaches. These medicines may also impart serious side-effects such as liver or kidney injury, heart problems, and even death. The seriousness of side-effects drives the need for innovative treatment technologies, such as human microbiome therapeutics, that have reduced the negative impact on the human body. The demand for microbiome therapeutics is increasing since it provides treatment sans chemicals.

Market Analysis and Insights: Global Human Microbiome Therapeutics Market
The global Human Microbiome Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Human Microbiome Therapeutics Scope and Market Size
Human Microbiome Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Human Microbiome Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Enterome Bioscience
Rebiotix
Seres Therapeutics
Vedanta Biosciences
Bristol-Myers Squibb
Johnson & Johnson
Takeda Pharmaceutical

Market segment by Type, the product can be split into
FMT
Microbiome Drugs
Market segment by Application, split into
C. difficile
Crohn’s Disease
Inflammatory Bowel Disease
Diabetes
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Human Microbiome Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Human Microbiome Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 FMT
1.4.3 Microbiome Drugs
1.5 Market by Application
1.5.1 Global Human Microbiome Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 C. difficile
1.5.3 Crohn’s Disease
1.5.4 Inflammatory Bowel Disease
1.5.5 Diabetes
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Human Microbiome Therapeutics Market Perspective (2015-2026)
2.2 Global Human Microbiome Therapeutics Growth Trends by Regions
2.2.1 Human Microbiome Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Human Microbiome Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Human Microbiome Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Human Microbiome Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Human Microbiome Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Human Microbiome Therapeutics Players by Market Size
3.1.1 Global Top Human Microbiome Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Human Microbiome Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Human Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Human Microbiome Therapeutics Market Concentration Ratio
3.2.1 Global Human Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Human Microbiome Therapeutics Revenue in 2019
3.3 Human Microbiome Therapeutics Key Players Head office and Area Served
3.4 Key Players Human Microbiome Therapeutics Product Solution and Service
3.5 Date of Enter into Human Microbiome Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Human Microbiome Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Human Microbiome Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Human Microbiome Therapeutics Market Size by Application (2015-2020)
5.2 Global Human Microbiome Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Human Microbiome Therapeutics Market Size (2015-2020)
6.2 Human Microbiome Therapeutics Key Players in North America (2019-2020)
6.3 North America Human Microbiome Therapeutics Market Size by Type (2015-2020)
6.4 North America Human Microbiome Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Human Microbiome Therapeutics Market Size (2015-2020)
7.2 Human Microbiome Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Human Microbiome Therapeutics Market Size by Type (2015-2020)
7.4 Europe Human Microbiome Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Human Microbiome Therapeutics Market Size (2015-2020)
8.2 Human Microbiome Therapeutics Key Players in China (2019-2020)
8.3 China Human Microbiome Therapeutics Market Size by Type (2015-2020)
8.4 China Human Microbiome Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Human Microbiome Therapeutics Market Size (2015-2020)
9.2 Human Microbiome Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Human Microbiome Therapeutics Market Size by Type (2015-2020)
9.4 Japan Human Microbiome Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Human Microbiome Therapeutics Market Size (2015-2020)
10.2 Human Microbiome Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Human Microbiome Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Human Microbiome Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Human Microbiome Therapeutics Market Size (2015-2020)
11.2 Human Microbiome Therapeutics Key Players in India (2019-2020)
11.3 India Human Microbiome Therapeutics Market Size by Type (2015-2020)
11.4 India Human Microbiome Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Human Microbiome Therapeutics Market Size (2015-2020)
12.2 Human Microbiome Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Human Microbiome Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Human Microbiome Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Enterome Bioscience
13.1.1 Enterome Bioscience Company Details
13.1.2 Enterome Bioscience Business Overview
13.1.3 Enterome Bioscience Human Microbiome Therapeutics Introduction
13.1.4 Enterome Bioscience Revenue in Human Microbiome Therapeutics Business (2015-2020))
13.1.5 Enterome Bioscience Recent Development
13.2 Rebiotix
13.2.1 Rebiotix Company Details
13.2.2 Rebiotix Business Overview
13.2.3 Rebiotix Human Microbiome Therapeutics Introduction
13.2.4 Rebiotix Revenue in Human Microbiome Therapeutics Business (2015-2020)
13.2.5 Rebiotix Recent Development
13.3 Seres Therapeutics
13.3.1 Seres Therapeutics Company Details
13.3.2 Seres Therapeutics Business Overview
13.3.3 Seres Therapeutics Human Microbiome Therapeutics Introduction
13.3.4 Seres Therapeutics Revenue in Human Microbiome Therapeutics Business (2015-2020)
13.3.5 Seres Therapeutics Recent Development
13.4 Vedanta Biosciences
13.4.1 Vedanta Biosciences Company Details
13.4.2 Vedanta Biosciences Business Overview
13.4.3 Vedanta Biosciences Human Microbiome Therapeutics Introduction
13.4.4 Vedanta Biosciences Revenue in Human Microbiome Therapeutics Business (2015-2020)
13.4.5 Vedanta Biosciences Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview
13.5.3 Bristol-Myers Squibb Human Microbiome Therapeutics Introduction
13.5.4 Bristol-Myers Squibb Revenue in Human Microbiome Therapeutics Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Details
13.6.2 Johnson & Johnson Business Overview
13.6.3 Johnson & Johnson Human Microbiome Therapeutics Introduction
13.6.4 Johnson & Johnson Revenue in Human Microbiome Therapeutics Business (2015-2020)
13.6.5 Johnson & Johnson Recent Development
13.7 Takeda Pharmaceutical
13.7.1 Takeda Pharmaceutical Company Details
13.7.2 Takeda Pharmaceutical Business Overview
13.7.3 Takeda Pharmaceutical Human Microbiome Therapeutics Introduction
13.7.4 Takeda Pharmaceutical Revenue in Human Microbiome Therapeutics Business (2015-2020)
13.7.5 Takeda Pharmaceutical Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Enterome Bioscience、Rebiotix、Seres Therapeutics、Vedanta Biosciences、Bristol-Myers Squibb、Johnson & Johnson、Takeda Pharmaceutical

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のヒトマイクロバイオーム治療薬市場2026:インサイト・予測(Global Human Microbiome Therapeutics Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。